Prime Medicine, Inc. ( (PRME) ) has released its Q4 earnings. Here is a breakdown of the information Prime Medicine, Inc. presented to its investors.
Prime Medicine, Inc., a biotechnology company specializing in gene editing therapies, has reported its financial results for the year 2024, highlighting significant progress in its clinical and preclinical programs. The company is on track to release initial data from its Phase 1/2 clinical trial of PM359 for chronic granulomatous disease in 2025 and is advancing its PM577 program for Wilson’s Disease with a planned IND filing in 2026. Financially, Prime Medicine reported a net loss of $195.9 million for 2024, slightly improved from the previous year, with increased R&D and G&A expenses contributing to the loss. However, the company’s cash position strengthened to $204.5 million, expected to support operations into 2026. Looking ahead, Prime Medicine remains focused on advancing its pipeline and exploring strategic partnerships to maximize the potential of its Prime Editing platform.